Meeting
2024 ASCO Gastrointestinal Cancers Symposium
The prognostic value of mutational signatures in pancreatic cancer.
Authors
Nicholas Light
University of Toronto, Toronto, ON, Canada
Nicholas Light , Amy Zhang , Oumaima Hamza , Gun Ho Jang , Anna Dodd , Julie Wilson , Grainne M. O'Kane , Erica S Tsang , Faiyaz Notta , Jennifer J. Knox , Steven Gallinger , Robert C Grant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 689)
DOI
10.1200/JCO.2024.42.3_suppl.689
Abstract #
689
Poster Bd #
M18
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx).
First Author: Michael J. Pishvaian
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen
Poster
2013 ASCO Annual Meeting
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
First Author: Heike Richly
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Advanced pancreatic cancer outcomes and the impact of COVID-19 pandemic: The experience of an academic cancer center.
First Author: Christian Adams-Carey